Quick Answer
Aptevo Therapeutics Inc. reported Total Assets of $27.19 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed an increase of +74.4% in Total Assets from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2016: $100.62 million | Q1 2017: $97.79 million | Q2 2017: $86.89 million | Q3 2017: $131.02 million | Q1 2018: $100.21 million | Q2 2018: $90.00 million | Q3 2018: $78.93 million | Q1 2019: $80.84 million | Q2 2019: $66.13 million | Q3 2019: $60.56 million | Q1 2020: $25.24 million | Q2 2020: $18.51 million | Q3 2020: $37.42 million | Q1 2021: $68.75 million | Q2 2021: $71.47 million | Q3 2021: $64.01 million | Q1 2022: $45.18 million | Q2 2022: $38.80 million | Q3 2022: $31.70 million | Q1 2023: $34.97 million | Q2 2023: $28.91 million | Q3 2023: $27.13 million | Q1 2024: $17.63 million | Q2 2024: $14.92 million | Q3 2024: $15.15 million | Q1 2025: $8.34 million | Q2 2025: $15.62 million | Q3 2025: $27.00 million.
- Over the full 13 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Total Assets has declined by 78.7%.
- Historical annual values: Fiscal year 2025: $27.19 million | Fiscal year 2024: $15.59 million | Fiscal year 2023: $24.84 million | Fiscal year 2022: $34.22 million | Fiscal year 2021: $56.60 million | Fiscal year 2020: $53.55 million | Fiscal year 2019: $53.41 million | Fiscal year 2018: $67.49 million | Fiscal year 2017: $117.01 million | Fiscal year 2016: $91.86 million | Fiscal year 2016: $133.47 million | Fiscal year 2016: $127.92 million | Fiscal year 2015: $127.77 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: